Skip to main content
SpringerLink
Log in

Diagnostisches und therapeutisches Vorgehen beim Nebennierenrindenkarzinom

  • Topic
  • Published:
best practice onkologie Aims and scope

Zusammenfassung

Das Nebennierenrindenkarzinom ist ein seltenes, aber aggressives Malignom mit i. Allg. schlechter Prognose. Internationale Kooperationen der letzten 10 Jahre haben es ermöglicht, das diagnostische Vorgehen zu standardisieren und therapeutische Strategien zu evaluieren. Die Therapie des Nebennierenrindenkarzinoms ist interdisziplinär und multimodal, jedoch gibt es nur wenige Fortschritte in der Entwicklung neuer effektiver Therapien. Die vollständige chirurgische Resektion ist die einzige kurative Option. Die Behandlung mit Mitotan besitzt sowohl in der adjuvanten Situation als auch im fortgeschrittenen Stadium eine herausragende Bedeutung.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Arlt W, Biehl M, Taylor AE et al. (2011) Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors. J Clin Endocrinol Metab 96:3775–3784

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  2. Bauditz J, Quinkler M, Wermke W (2009) Radiofrequency thermal ablation of hepatic metastases of adrenocortical cancer-a case report and review of the literature. Exp Clin Endocrinol Diabetes 117:316–319

    Article  CAS  PubMed  Google Scholar 

  3. Bellantone R, Lombardi CP, Raffaelli M (2014) What is the appropriate role of minimally invasive vs. open surgery for small adrenocortical cancers? Curr Opin Oncol 27(1):44–49

    Article  Google Scholar 

  4. Berruti A, Sperone P, Bellini E et al. (2011) Metronomic therapy concepts in the management of adrenocortical carcinoma. Horm Cancer 2:378–384

    Article  CAS  PubMed  Google Scholar 

  5. Brix D, Allolio B, Fenske W et al. (2010) Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients. Eur Urol 58:609–615

    Article  PubMed  Google Scholar 

  6. Chacon R, Tossen G, Loria FS et al. (2005) CASE 2. Response in a patient with metastatic adrenal cortical carcinoma with thalidomide. J Clin Oncol 23:1579–1580

    Article  PubMed  Google Scholar 

  7. De Francia S, Ardito A, Daffara F et al. (2012) Mitotane treatment for adrenocortical carcinoma: an overview. Minerva Endocrinol 37:9–23

    CAS  PubMed  Google Scholar 

  8. Donatini G, Caiazzo R, Do Cao C et al. (2014) Long-term survival after adrenalectomy for stage I/II adrenocortical carcinoma (ACC): a retrospective comparative cohort study of laparoscopic versus open approach. Ann Surg Oncol 21:284–291

    Article  PubMed  Google Scholar 

  9. Else T, Kim AC, Sabolch A et al. (2014) Adrenocortical carcinoma. Endocr Rev 35:282–326

    Article  CAS  PubMed  Google Scholar 

  10. Erdogan I, Deutschbein T, Jurowich C et al. (2013) The role of surgery in the management of recurrent adrenocortical carcinoma. J Clin Endocrinol Metab 98:181–191

    Article  CAS  PubMed  Google Scholar 

  11. Fassnacht M, Allolio B (2010) What is the best approach to an apparently nonmetastatic adrenocortical carcinoma? Clin Endocrinol 73:561–565

    Article  CAS  Google Scholar 

  12. Fassnacht M, Hahner S, Polat B et al. (2006) Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. J Clin Endocrinol Metab 91:4501–4504

    Article  CAS  PubMed  Google Scholar 

  13. Fassnacht M, Johanssen S, Fenske W et al. (2010) Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers. J Clin Endocrinol Metab 95:4925–4932

    Article  CAS  PubMed  Google Scholar 

  14. Fassnacht M, Johanssen S, Quinkler M et al. (2009) Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer 115:243–250

    Article  PubMed  Google Scholar 

  15. Fassnacht M, Kroiss M, Allolio B (2013) Update in adrenocortical carcinoma. J Clin Endocrinol Metab 98:4551–4564

    Article  CAS  PubMed  Google Scholar 

  16. Fassnacht M, Terzolo M, Allolio B et al. (2012) Combination chemotherapy in advanced adrenocortical carcinoma. New Engl J Med 366:2189–2197

    Article  CAS  PubMed  Google Scholar 

  17. Gagliano T, Gentilin E, Benfini K et al. (2014) Mitotane enhances doxorubicin cytotoxic activity by inhibiting P-gp in human adrenocortical carcinoma cells. Endocrine 47(3):943–951

    Article  CAS  PubMed  Google Scholar 

  18. Habscheid W, Pfeiffer M, Demmrich J et al. (1990) [Puncture track metastasis after ultrasound-guided fine-needle puncture biopsy. A rare complication?]. Dtsch Med Wochenschr 115:212–215

    Article  CAS  PubMed  Google Scholar 

  19. Hahner S, Kreissl MC, Fassnacht M et al. (2012) [131I]iodometomidate for targeted radionuclide therapy of advanced adrenocortical carcinoma. J Clin Endocrinol Metab 97:914–922

    Article  CAS  PubMed  Google Scholar 

  20. Hermsen IG, Fassnacht M, Terzolo M et al. (2011) Plasma concentrations of o,p’DDD, o,p’DDA, and o,p’DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. J Clin Endocrinol Metab 96:1844–1851

    Article  CAS  PubMed  Google Scholar 

  21. Jones RL, Kim ES, Nava-Parada P et al. (2014) Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors. Clin Cancer Res: 2014 Sep 10. [Epub ahead of print]

    Google Scholar 

  22. Kerkhofs TM, Baudin E, Terzolo M et al. (2013) Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma. J Clin Endocrinol Metab 98:4759–4767

    Article  CAS  PubMed  Google Scholar 

  23. Kerkhofs TM, Verhoeven RH, Bonjer HJ et al. (2013) Surgery for adrenocortical carcinoma in The Netherlands: analysis of the national cancer registry data. Eur J Endocrinol 169:83–89

    Article  CAS  PubMed  Google Scholar 

  24. Kroiss M, Quinkler M, Johanssen S et al. (2012) Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial. J Clin Endocrinol Metab 97:3495–3503

    Article  CAS  PubMed  Google Scholar 

  25. Kroiss M, Quinkler M, Lutz WK et al. (2011) Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma. Clin Endocrinol 75:585–591

    Article  CAS  Google Scholar 

  26. Lerario AM, Worden FP, Ramm CA et al. (2014) The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial. Horm Cancer 5:232–239

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  27. Lombardi CP, Raffaelli M, Boniardi M et al. (2012) Adrenocortical carcinoma: effect of hospital volume on patient outcome. Langenbecks Arch Surg 397:201–207

    Article  PubMed  Google Scholar 

  28. Lombardi CP, Raffaelli M, De Crea C et al. (2012) Open versus endoscopic adrenalectomy in the treatment of localized (stage I/II) adrenocortical carcinoma: results of a multiinstitutional Italian survey. Surgery 152:1158–1164

    Article  PubMed  Google Scholar 

  29. Miller BS, Gauger PG, Hammer GD et al. (2012) Resection of adrenocortical carcinoma is less complete and local recurrence occurs sooner and more often after laparoscopic adrenalectomy than after open adrenalectomy. Surgery 152:1150–1157

    Article  PubMed  Google Scholar 

  30. Mir MC, Klink JC, Guillotreau J et al. (2013) Comparative outcomes of laparoscopic and open adrenalectomy for adrenocortical carcinoma: single, high-volume center experience. Ann Surg Oncol 20:1456–1461

    Article  PubMed  Google Scholar 

  31. Nelson AA, Woodard G (1948) Adrenal cortical atrophy and liver damage produced in dogs by feeding 2,2-bis-(parachloro-phenyl)-1,1-dichloroethane. Federation Proc 7:277

    CAS  Google Scholar 

  32. Reibetanz J, Jurowich C, Erdogan I et al. (2012) Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma. Ann Surg 255:363–369

    Article  PubMed  Google Scholar 

  33. Ripley RT, Kemp CD, Davis JL et al. (2011) Liver resection and ablation for metastatic adrenocortical carcinoma. Ann Surg Oncol 18:1972–1979

    Article  PubMed Central  PubMed  Google Scholar 

  34. Ronchi CL, Kroiss M, Sbiera S et al. (2014) EJE prize 2014: current and evolving treatment options in adrenocortical carcinoma: where do we stand and where do we want to go? Eur J Endocrinol 171:R1–R11

    Article  CAS  PubMed  Google Scholar 

  35. Sperone P, Ferrero A, Daffara F et al. (2010) Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. Endoc Relat Cancer 17:445–453

    Article  CAS  Google Scholar 

  36. Terzolo M, Angeli A, Fassnacht M et al. (2007) Adjuvant mitotane treatment for adrenocortical carcinoma. New Engl J Med 356:2372–2380

    Article  CAS  PubMed  Google Scholar 

  37. Terzolo M, Daffara F, Ardito A et al. (2014) Management of adrenal cancer: a 2013 update. J Endocinol Invest 37:207–217

    Article  CAS  Google Scholar 

  38. Tran TB, Liou D, Menon VG et al. (2013) Surgical management of advanced adrenocortical carcinoma: a 21-year population-based analysis. Am Surg 79:1115–1118

    PubMed  Google Scholar 

  39. Williams AR, Hammer GD, Else T (2014) Transcutaneous biopsy of adrenocortical carcinoma is rarely helpful in diagnosis, potentially harmful, but does not affect patient outcome. Eur J Endocrinol 170:829–835

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Med. Klinik m.S. Endokrinologie, Diabetes und Ernährungsmedizin, Charité - Universitätsmedizin Berlin, Berlin, Deutschland

    Tina Kienitz

  2. Klinik für Allgemein-, Visceral- und Transplantationschirurgie, Campus Virchow-Klinikum, Charité - Universitätsmedizin Berlin, Berlin, Deutschland

    Nada Rayes

  3. Stuttgarter Platz, Berlin, Deutschland

    Marcus Quinkler (Endokrinologiepraxis)

  4. Stuttgarter Platz, Stuttgarter Platz 1, 10627, Berlin, Deutschland

    Marcus Quinkler (Endokrinologiepraxis)

Authors
  1. Tina Kienitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nada Rayes
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marcus Quinkler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marcus Quinkler.

Additional information

Einhaltung ethischer Richtlinien

Interessenkonflikt. T. Kienitz und M. Quinkler haben an einer Studie, gesponsert von Astellas Pharma, zur Wirkung des IGF1-Rezeptor-Antagonisten OSI-906 teilgenommen. M. Quinkler wurde für einzelne Studienprojekte von HRA Pharma und Pfizer unterstützt.

T. Kienitz, N. Rayes und M. Quinkler geben an, dass kein Interessenkonflikt bezüglich dieses Artikels besteht.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kienitz, T., Rayes, N. & Quinkler, M. Diagnostisches und therapeutisches Vorgehen beim Nebennierenrindenkarzinom. best practice onkologie 10, 42–49 (2015). https://doi.org/10.1007/s11654-014-0520-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11654-014-0520-3

Search

Navigation